Search Follow us

BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3678.6m
Last closeCHF66.40
High / Low (52 weeks)CHF73.4 / CHF58.5
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Other companies in sector Show

Aberdeen New Dawn Investment Trust Aberdeen New Thai Investment Trust
Aberdeen Private Equity Fund Aberdeen UK Tracker Trust
AcenciA Debt Strategies Acorn Income Fund
Adamas Finance Asia Alliance Trust
Altamir SCA Amphion Innovations
Aurelius Bailador Tech Investments
Bankers Investment Trust (The) BioPharma Credit
BlackRock Greater Europe Investment Trust BlackRock Hedge Selector
BlackRock Latin American Inv. Trust British Portfolio Trust
Brunner Investment Trust (The) Canadian General Investments
Carador Income Fund CFP Sanford DeLand Free Spirit Fund.
Charles Stanley City Natural Resources
Conversus Capital CQS Rig Finance Fund
CVC Credit Partners European Opps Detour Gold
Deutsche Beteiligungs Dexion Commodities
Diverse Income Trust (The) DouglasBay Capital
Dunedin Enterprise Investment Trust DW Catalyst Fund
Edinburgh Worldwide Investment Trust (The) European Assets Trust
European Investment Trust (The) F&C Managed Portfolio Income
F&C Managed Portfolio Trust F&C US Smaller Companies
Fidelity China Special Situations Fidelity European Values
Finsbury Growth & Income Trust Foreign & Colonial Investment Trust
Gartmore Growth Opportunities Gartmore Irish Growth Fund
Geiger Counter Limited Genesis Emerging Markets Fund
GLI Alternative Finance Global Resources Investment Trust
Golden Prospect Precious Metals Gulf Investment Fund
Hansa Trust (HAN) HarbourVest Global Private Equity
HarbourVest Senior Loans Europe HBM Healthcare Investments
Heliad Equity Partners Henderson Alternative Strategies Trust
Henderson Far East Income Henderson Global Trust
Henderson Global Trust Henderson International Income Trust
Heptagon HSBC Infrastructure Company
Infrastructure India International Biotechnology Trust
Invesco Asia Trust Invesco Income Growth Trust
Is Private Equity JP Morgan Private Equity Limited
JPMorgan Brazil Investment Trust JPMorgan European Smaller Companies Trust
JPMorgan Global Convertibles Income Fund JPMorgan Global Growth & Income
JPMorgan Indian Investment Trust Jupiter Green Investment Trust
Jupiter UK Growth Investment Trust Jupiter US Smaller Companies
JZ Capital Partners Limited Lazard World Trust Fund
Leaf Clean Energy Company LMS Capital
Lowland Investment Company LPEQ
Marble Point Loan Financing Martin Currie Asia Unconstrained Trust
Martin Currie Global Portfolio Trust Middlefield Canadian Income
Miton Global Opportunities Miton Income Opportunities Trust
New City Energy Ocean Wilsons Holdings
Odyssean Investment Trust Pacific Assets Trust
Phaunos Timber Fund Polar Capital Global Healthcare Trust
Princess Private Equity Holding PXP Vietnam Fund
Rathbone Brothers RENN Universal Growth Investment Trust
Schroder AsiaPacific Fund Schroder Global Real Estate Securities
ScotGems Scottish Oriental Smaller Companies
Securities Trust of Scotland Seneca Global Income & Growth Trust
Sigma Capital Group Standard Life Equity Income Trust
Standard Life Investments Property Income Trust Standard Life Private Equity Trust
Standard Life UK Smaller Companies Strategic Equity Capital
Taiwan Fund (The) Templeton Emerging Markets Investment Trust
Tetragon Financial Group The Biotech Growth Trust
The Law Debenture Corporation The Merchants Trust
The North American Income Trust The Scottish Investment Trust
Tiso Blackstar Group TR European Growth Trust
UK Commercial Property REIT Utilico Emerging Markets
Vietnam Enterprise Investments Vietnam Holding Asset Management
Vietnam Infrastructure Fund VinaCapital Vietnam Opportunity Fund
VinaLand Vision Opportunity China Fund
WAM Active WAM Capital
WAM Research Witan Investment Trust
Witan Pacific Investment Trust Worldwide Healthcare Trust
YFM Equity Partners

Company news

Investment summary

BB Biotech (BION) is a long-established (since 1993), Switzerland-based global investor in the innovative area of biotechnology. It is differentiated from peers by its short list of stocks (typically 30-35) and high-conviction approach, with five to eight core holdings accounting for half to two-thirds of the portfolio. While the fund can be vulnerable to short-term sentiment dips (such as in the period immediately before and after the US presidential election in 2016), its performance record is impressive in both absolute and relative terms, with a NAV total return of c 270% over five years, and NAV and share price outperformance of the benchmark NASDAQ Biotechnology index over three, six and 12 months, and three, five and 10 years to 31 October 2017 (all in Swiss franc terms). A high distribution policy of 5.0% underpins the current dividend yield of 4.3%.

Last updated on 23/11/2017

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website